

Copyright (c) 1993-2000 Compuserp Ltd.

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Maximum file size: 4.5

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

ATTACHMENTS

RESULTS 1

AA081011

AA081011 standard: cDNA: 1156 bp.

AA081011:

13-FEB-2001 (first entry)

Human B1Aq1 and B1Aq1 isoform with 1% cDNA

Human, breast tumor, specific and human cytosolic variant

Human, breast cancer: B1Aq1: B1Aq1: 88.

Human, breast cancer: B1Aq1: B1Aq1: 88.

Human, breast cancer: B1Aq1: B1Aq1: 88.

Human, breast cancer: B1Aq1: B1Aq1: 88.

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

Human prostate tissue

PI breast cancer, and monitoring cancer progression in a patient -
 XX
 PS Claim 4: Page 177, 187pp: English.
 XX

CC The present sequence is given in a specification relating to compositions
 CC and methods for the treatment and diagnosis of breast cancer. Nucleotide
 CC sequences that are preferentially expressed in breast tumour tissue, and
 CC the polypeptides encoded by such nucleotide sequences, are used in
 CC compositions and vaccines to inhibit the development of cancer,
 CC especially breast cancer. The progression of a cancer may be monitored by
 CC carrying out detection of tumour specific antigens at subsequent time
 CC points and comparing the results from the different time points.
 CC CD4+ and/or CD8+ T-cells isolated from the cancer patient may be treated
 CC with tumour-specific polypeptides, polynucleotides encoding the
 CC polypeptides or antigen presenting cells expressing the polypeptides. The
 CC cells are then administered to the patient to inhibit development of
 CC cancer.

XX
 SQ Sequence 1155 BP: 346 A; 253 C; 297 G; 259 T; 0 other;

Query Match: 100 %, Score 1155; DB 21; Length 1155;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 1155; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 atgaggttggagttgattcctatgagcagcagcctctctgtgaagaacattgtgctc 60
 DB 1 atgaggttggagttgattcctatgagcagcagcctctctgtgaagaacattgtgctc 60
 QY 61 aagagcaaatgagcaaatgagcagcagcagcagcagcagcagcagcagcagcagcagc 120
 DB 61 aagagcaaatgagcaaatgagcagcagcagcagcagcagcagcagcagcagcagcagc 120
 QY 121 agcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 180
 DB 121 agcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 180
 QY 181 atgagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 240
 DB 181 atgagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 240
 QY 241 atgagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 300
 DB 241 atgagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 300
 QY 301 tggagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 360
 DB 301 tggagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 360
 QY 361 agagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 420
 DB 361 agagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 420
 QY 421 agagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 480
 DB 421 agagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 480
 QY 481 ctgagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 540
 DB 481 ctgagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 540
 QY 541 ctgagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 600
 DB 541 ctgagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 600
 QY 601 gtcctgagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 660
 DB 601 gtcctgagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 660
 QY 661 tggagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 720
 DB 661 tggagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 720

QY 721 accactgcaactgacagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 780
 DB 721 accactgcaactgacagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 780
 QY 781 tggagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 840
 DB 781 tggagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 840
 QY 841 catgagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 900
 DB 841 catgagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 900
 QY 901 ctgagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 960
 DB 901 ctgagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 960
 QY 961 gtcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 1020
 DB 961 gtcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 1020
 QY 1021 gtcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 1080
 DB 1021 gtcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 1080
 QY 1081 aagagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 1140
 DB 1081 aagagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 1140
 QY 1141 accagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 1200
 DB 1141 accagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 1200

RESULT 2
 AAA06598
 ID AAA06598 standard; cDNA; 1155 BP.
 AC AAA06598;
 XX
 XX
 DT 13-JUN-2000 (first entry)
 XX
 DE Human immunogenic prostate tumour protein cDNA sequence SEQ ID NO:373.
 KW Human; prostate cancer; diagnosis; tumour; gene therapy; detection;
 KW immunogenic; cytosolic; vaccine; ss
 OS Homo sapiens.
 XX
 PN W0200004149-A2.
 PD 27-JAN-2000.
 XX
 PE 14-JUN-1999; 99W0-S15838.
 XX
 PR 14-JUN-1998; 98US-0116453.
 PR 14-JUN-1998; 98US-0116134.
 PR 23-SEP-1998; 98US-0159812.
 PR 23-SEP-1998; 98US-0159812.
 PR 15-JAN-1999; 99US-0232149.
 PR 15-JAN-1999; 99US-0232880.
 PR 09-APR-1999; 99US-0288946.
 XX
 PA (CORR-) CORLIXA CORP.
 XX
 PI Dillon DC, Harlocker SL, Yagin T, Xu J, Mitcham JL;
 DR WPI: 2000-171268/15.
 XX
 PT New polypeptide useful for treating and diagnosing prostate cancer
 PT comprises an immunogenic portion of prostate tumor protein -
 PS Claim 50; Page 222; 263pp; English.
 XX

[illegible][illegible]

[illegible][illegible]

[illegible][illegible]

Sat Mar 9 09:57:24 2002

us-09-699-295-301_1.rng

Facet #	Score	Quality	Length	DB	ID	Description
1	492.2	42.6	86.5	11	h6576397	h6576397 602084215
2	438.8	60.2	84.3	10	A0120946	A0120946 A0120946
3	475.5	5.9	10	A0910780	A0910780 6148B04.8	
4	296.2	26.0	69.4	11	h65720647	h65720647 6026942528
5	251.2	21.2	17.8	12	AK013783	AK013783 M05. music
6	217.6	18.8	74.7	11	h65717440	h65717440 602689791
7	217.6	18.8	10.4	12	AK015948	AK015948 M05. music
8	213.6	18.5	82.2	11	h65705057	h65705057 602146651
9	211.6	18.3	81.0	11	h65704846	h65704846 602686889
10	209.6	18.1	90.7	11	h65721483	h65721483 602695061
11	207.8	18.0	91.6	11	h65716673	h65716673 602689005
12	207.4	18.0	104.2	12	AK016475	AK016475 M05. music

ACKNOWLEDGMENTS

[illegible]

Zeteticism "Home sapiens"
Zib word "Zion": 9606^m
Zilcano "IMate: 4.248746"
Zilcano, lib "NH Me: 84"
Zlob host "PHIO: (IL) host-restaurant"
Zloty "argent; prostitute; Vector: pink lib (color=?)"

COMMENT Please visit our web site (<http://genome.gov>) for further details

FEATURES	Location/Qualifiers
source	1. .1054

```

"date": "2024-10-08",
"foodon_start": 1,
"/protein_id": "BAH30047.1",
"/db_xref": "GI:12854491",
"translation": "MKFFPFRPKRTSHSHSVPLAKTAIAPNLSICVYLI  

DRHAKSLAALISNEQKITYLEFKNVWSPFSEFLDANSTYIVSLI  

NQRKIIVSNPPTPLKAVELGDSCTVILLGAPNIVQVSTAIHVAWGN  

SLANKILOYKANIAPKNDGHPILLIIVANNEMVPLLKQADNASDKRI  

IAIIVPTSSVKLLDQRTPLAKRTIVSTAFVANSNLTPIHHTITAN  

TAV",
"length": 1033,
"md5sum": "1033..1038"
}

```

PolyA_signal	1033	1038	
	/note="putative"		
PolyA_site	1054		
	/note="putative"		
BASE COUNT	346	206	207
		200	2
		others	

Query Match	18.8%;	Score 217.6;	DB 12;	Length 1054;
Best Local Similarity	56.6%;	Pred. No. 3,1642;		
Matches 403;	Conservative 0;	Mismatches 309;	Indels 0;	Gaps 0;

[illegible]

Sat Mar 9 09:57:25 2002

us-09-699-295-301_1.rst

Page 14

Search completed: March 9, 2002, 01:50:43
Job time: 4922 sec

• • •


```

|||||
Db 1 atggtgttggatgttgcattgcacgtgcctctctcttgaaagagccatttgcttc 60
OY 61 agagagcaatgagcaatgagatgagatgagatgagatgagatgagatgagatgag 120
Db 61 agagagcaatgagcaatgagatgagatgagatgagatgagatgagatgagatgag 120
OY 121 agagagcaatgagcaatgagatgagatgagatgagatgagatgagatgagatgag 180
Db 121 agagagcaatgagcaatgagatgagatgagatgagatgagatgagatgagatgag 180
OY 181 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 240
Db 181 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 240
OY 241 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 300
Db 241 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 300
OY 301 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 360
Db 301 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 360
OY 361 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 420
Db 361 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 420
OY 421 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 480
Db 421 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 480
OY 481 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 540
Db 481 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 540
OY 541 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 600
Db 541 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 600
OY 601 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 660
Db 601 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 660
OY 661 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 720
Db 661 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 720
OY 721 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 780
Db 721 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 780
OY 781 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 840
Db 781 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 840
OY 841 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 900
Db 841 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 900
OY 901 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 960
Db 901 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 960
OY 961 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 1020
Db 961 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 1020
OY 1021 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 1080
Db 1021 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 1080
OY 1081 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 1140
Db 1081 atgagcaatgagatgagatgagatgagatgagatgagatgagatgagatgagatg 1140

```

```

Db 1081 aaataaaacagatgcataaaatctctctgaataacagatgcataaaatgcataaa 1140
OY 1141 accagataataaa 1155
Db 1141 accagataataaa 1155
RESULT 6
ACB81012
ACB81012: standard, CINA: 2007 BP
ACB81012:
13-FEB-2001 (first entry)
Human B11A1 antigen splice isoform B11C-8 cDNA.
Human breast tumour-specific antigen; cytostatic vaccine;
breast cancer; B18A1; B11A1; B15A1; ss.
Homo sapiens.
W0200061753-A2.
19-OCT-2000.
07 APR 2009: 2000W0-0509312.
09-APR-1999: 609S-0284108.
28-OCT-1999: 609S-0420755.
23-MAR-2000: 2000US-0534825.
(CORI-) CORIXA CORP.
Erddakis TN, Smith JM, Reed SG, Misher LE, Ketter MM, Ellison DC:
W01: 2000-6-28403/60.
P-PSDB: AAB28629.
An isolated polypeptide comprising an immunogenic portion of a breast
tumor protein used for inhibiting the development of cancer, especially
breast cancer, and monitoring cancer progression in a patient.
Claim 4, Page 177 178, 187pp, English.
The present sequence is given in a specification relating to compositions
and methods for the treatment and diagnosis of breast cancer. Nucleotide
sequences that are preferentially expressed in breast tumor tissue, and
the polypeptides encoded by such nucleotide sequences, are used in
compositions and various ways to inhibit the development of cancer,
especially breast cancer. The progression of a cancer may be monitored by
carrying out detection of tumor-specific antigens at subsequent time
points and comparing the results from the different time points.
T4; and/or CFB-T-Cells isolated from the cancer patient may be treated
with tumour-specific polypeptides, polynucleotides encoding the
polypeptides or antigen presenting cells expressing the polypeptides. The
cells are then administered to the patient to inhibit development of
cancer.
Sequence 2020 PP, 698 A; 388 C; 489 G; 425 T; 0 others;
Query Match 97.78, Score 1129, DB 21, Length 20 (9)
Post Local Similarity 100.0%; Pred. No. 0;
Matches 1128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 atggtgttggatgttgcattgcacgtgcctctctcttgaaagagccatttgcttc 60
Db 1 atggtgttggatgttgcattgcacgtgcctctctcttgaaagagccatttgcttc 60
OY 61 agagagcaatgagcaatgagatgagatgagatgagatgagatgagatgagatgag 120
Db 61 agagagcaatgagcaatgagatgagatgagatgagatgagatgagatgagatgag 120

```


[illegible]

RESULTS /
ANALYSIS
(1) ANALYSIS, standard, copoly, 2000-60

[illegible]

[illegible][illegible]

```

|||||
Db 601 gtcttggcaacaaagaaagagagctctatgaagagcctatgaatctcagagagatgaa 660
QY 661 ttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt 720
Db 661 ttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt 720
QY 721 accatctgagctgagctgagctgagctgagctgagctgagctgagctgagctgagctg 780
Db 721 accatctgagctgagctgagctgagctgagctgagctgagctgagctgagctgagctg 780
QY 781 ttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt 840
Db 781 ttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt 840
QY 841 ttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt 900
Db 841 ttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt 900
QY 901 ttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt 960
Db 901 ttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt 960
QY 961 ttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt 1020
Db 961 ttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt 1020
QY 1021 ttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt 1080
Db 1021 ttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt 1080
QY 1081 ttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt 1128
Db 1081 ttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt 1128

RESULT 10
AAC81013
ID AAC81013 standard; cDNA, 2040 bp
XX
AC AAC81013;
XX
DI 13-FEB-2001 (first entry)
XX
DE Human B11A1 antigen splice isoform B11C-9-16 cDNA.
XX
KW Human breast tumour-specific antigen; cytosolic; vaccine;
KW breast cancer; B18A1; B11A1; B15A1; ss.
XX
OS Homo sapiens.
XX
PN W020061753-A2.
XX
PD 19-OCT-2000.
XX
PE 07-APR-2000; 2000W/08/0312.
XX
PR 09-APR-1999; 990S-0289198.
PR 28-OCT-1999; 990S-0429755.
PR 23-MAR-2000; 2000US-0534825.
XX
PA (CORI-) CORIAX CORP.
XX
PI Fridakis TN, Smith JM, Reed SG, Misher LE, Rottler MW, Dillon DC;
XX
DR WP1: 2000-628403/60.
XX
DR P-PSDB: AAB28630.
XX
PI An isolated polypeptide comprising an immunogenic portion of a breast
PI tumor protein used for inhibiting the development of cancer, especially
PI breast cancer, and monitoring cancer progression in a patient -
PS Claim 4; Page 178; 187pp; English.

```

```

XX
CC The present sequence is given in a specification relating to compositions
CC and methods for the treatment and diagnosis of breast cancer. Nucleotide
CC sequences that are preferentially expressed in breast tumor tissue, and
CC the polypeptides encoded by such nucleotide sequences, are used in
CC compositions and vaccines to inhibit the development of cancer,
CC especially breast cancer. The progression of a cancer may be monitored by
CC carrying out detection of tumor-specific antigens at subsequent time
CC points and comparing the results from the different time points.
CC C34 and C28 cells (derived from the same patient) may be treated
CC with tumour-specific polypeptides, polynucleotides encoding the
CC polypeptides or antigen presenting cells expressing the polypeptides. The
CC cells are then administered to the patient to inhibit development of
CC cancer.
XX
SQ Sequence 2040 bp; 716 A; 392 C; 500 G; 432 T; 0 other;
Query Match 97.7%; Score 1128; DB 21; Length 2040;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 atggttggttggttggttggttggttggttggttggttggttggttggttggttggttggt 60
Db 1 atggttggttggttggttggttggttggttggttggttggttggttggttggttggttggt 60
QY 61 aggaagaaagatgagcaatggttggttggttggttggttggttggttggttggttggttggt 120
Db 61 aggaagaaagatgagcaatggttggttggttggttggttggttggttggttggttggttggt 120
QY 121 agcaacgttggttggttggttggttggttggttggttggttggttggttggttggttggt 180
Db 121 agcaacgttggttggttggttggttggttggttggttggttggttggttggttggttggt 180
QY 181 atggcaagtggttggttggttggttggttggttggttggttggttggttggttggttggt 240
Db 181 atggcaagtggttggttggttggttggttggttggttggttggttggttggttggttggt 240
QY 241 atggcaagtggttggttggttggttggttggttggttggttggttggttggttggttggt 300
Db 241 atggcaagtggttggttggttggttggttggttggttggttggttggttggttggttggt 300
QY 301 tgggttggttggttggttggttggttggttggttggttggttggttggttggttggttggt 360
Db 301 tgggttggttggttggttggttggttggttggttggttggttggttggttggttggttggt 360
QY 361 ggaagctgagctgagctgagctgagctgagctgagctgagctgagctgagctgagctgagct 420
Db 361 ggaagctgagctgagctgagctgagctgagctgagctgagctgagctgagctgagctgagct 420
QY 421 gacagctgagctgagctgagctgagctgagctgagctgagctgagctgagctgagctgagct 480
Db 421 gacagctgagctgagctgagctgagctgagctgagctgagctgagctgagctgagctgagct 480
QY 481 ctcaagagctgagctgagctgagctgagctgagctgagctgagctgagctgagctgagctgagct 540
Db 481 ctcaagagctgagctgagctgagctgagctgagctgagctgagctgagctgagctgagctgagct 540
QY 541 tctggcaatgggttggttggttggttggttggttggttggttggttggttggttggttggttggt 600
Db 541 tctggcaatgggttggttggttggttggttggttggttggttggttggttggttggttggttggt 600
QY 601 gtcttggcaacaaagaaagagagctctatgaagagcctatgaatctcagagagatgaa 660
Db 601 gtcttggcaacaaagaaagagagctctatgaagagcctatgaatctcagagagatgaa 660
QY 661 ttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt 720
Db 661 ttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt 720
QY 721 accatctgagctgagctgagctgagctgagctgagctgagctgagctgagctgagctgagctg 780
Db 721 accatctgagctgagctgagctgagctgagctgagctgagctgagctgagctgagctgagctg 780

```

[illegible][illegible]

The present invention describes isolated polypeptides, comprising an immunogenic portion of a prostatic tumour protein (PTP). The polypeptide and polynucleotides encoding them have representative activity and can be used as vaccines and in gene therapy. The polypeptide which expresses PTP may also be fused to other proteins or peptides which express the desired properties, and methods exist for the polypeptide and variants containing them can be used for inhibiting the development of prostate cancer.

	Query Match	97.7%	Score 11285	10-21%	Len 416	2046
	Host Label Similarity	100.0%	Prod. No. 02			
	Matches 11285	Conservative 02	Mismatch 02	Indel 02	Gap 02	
cy	1					
db	1					
cy	61					
db	61					
cy	121					
db	121					
cy	181					
db	181					
cy	241					
db	241					
cy	301					
db	301					
cy	361					
db	361					
cy	421					
db	421					
cy	481					
db	481					
cy	541					
db	541					
cy	601					
db	601					
cy	661					
db	661					
cy	721					
db	721					
cy	781					
db	781					
cy	841					
db	841					

QY 901 ctgataaataaagagagctctcacttctgtatgttggatcagaagata 960
 Db 901 ctgataaataaagagagctctcacttctgtatgttggatcagaagata 960
 QY 961 gtacagcttctacttgaagaataatataatctctcactcagaatctctgacagag 1020
 Db 961 gtacagcttctacttgaagaataatataatctctcactcagaatctctgacagag 1020
 QY 1021 gccaagagatagctgttctctgactcactcgaatttcgcaattctgactac 1080
 Db 1021 gccaagagatagctgttctctgactcactcgaatttcgcaattctgactac 1080
 QY 1081 aagaagaagaagatgtaaaatctcttctgaaagacagatctcagaa 1120
 Db 1081 aagaagaagaagatgtaaaatctcttctgaaagacagatctcagaa 1120
 RESULT 12
 AAH93716 standard: cDNA: 2040 bp
 AC AAH93716:
 DI 04-ECT-2001 (first entry)
 DE Human prostate-specific cDNA sequence B305D splice variant #10.
 KW Human: prostate cancer; Prostate-specific; diagnosis; vaccine;
 KW cytostatic; gene therapy; metastasis; ss.
 OS Homo sapiens.
 PN W020015163-A2.
 PD 19-JUL-2001.
 PE 16-JAN-2001: 2001WO-US01574.
 PR 14-JAN-2000: 2000US-0483672.
 PA (CORI-) CORIXA CORP.
 PI Xu J., Dillon D., Mitcham H., Harlocker S.L., Jiang Y., Reed S.G.,
 PI Kline M.D., Harper J.B., Dry W.B., Weller W.M., Smith J.A., Shelly Y.M.,
 PI Ward A., Meagher M.J.
 DR WI: 2001 426873/45.
 PT New polynucleotide encoding a prostate-specific protein, for
 PT diagnosis, monitoring and treating prostate cancer in a patient and
 PT for use in vaccines.
 PS claim 1: Page 348: 543pp: English.
 XX The present invention describes polynucleotide sequences (I) which encode
 XX prostate-specific proteins (II) (I) and (II) have cytostatic activity,
 XX and can be used in vaccine production and gene therapy. (I), (II),
 XX antibodies to (I), fusion proteins comprising (I), and isolated
 XX cells prepared using (I) or (II) are used treat cancer in a patient.
 XX (I) and the antibodies are also used in the detection of cancer in a
 XX patient. The cancer that is diagnosed or treated is particularly
 XX prostate cancer. (I) and (II) can be used in vaccines. The antibodies or
 XX (I) can be used for monitoring the progression of cancer in a patient.
 XX (I) and (II) can also be used to improve diagnostic and therapeutic
 XX methods for prostate cancer. They can indicate the level of metastasis
 XX as well as the prostate volume. AAH93757 to AAH93944 and AAH01115 to
 XX AAH01318 represent polynucleotide and amino acid sequences used in the
 XX exemplification of the present invention.
 SQ Sequence 2040 bp: 716 A, 392 C, 580 G, 432 T, 0 other.

Query Match 97.7%, Score 1128, E=23, Length 2010
 Most Identical Similarity 100.0%, Pct Ident 97.7%, Gaps 0
 Matches 1128, Conserved 0, Mismatches 0, Indels 0, Gaps 0
 QY 1 atagtggttgaaatgattccatgcagagctgctctctggaagaacacattgactc 60
 Db 1 atagtggttgaaatgattccatgcagagctgctctctggaagaacacattgactc 60
 QY 61 aagaagaataggaatgagtgctgacattggttccctgctcagaagaagagagaa 120
 Db 61 aagaagaataggaatgagtgctgacattggttccctgctcagaagaagagagaa 120
 QY 121 atcaacgttgagactctctggaagacagagagactctgataaagatgactcagagca 180
 Db 121 atcaacgttgagactctctggaagacagagagactctgataaagatgactcagagca 180
 QY 181 atgaggaatgagtgagagagagctgctctccctgctcagagagagatgagaaacag 240
 Db 181 atgaggaatgagtgagagagagctgctctccctgctcagagagagatgagaaacag 240
 QY 241 ggcagctctggaagacacagagagactctgataaagagactcagagacagatgagaa 300
 Db 241 ggcagctctggaagacacagagagactctgataaagagactcagagacagatgagaa 300
 QY 301 tatgtctgagagctgctctccctgctcagagagagagagagagagagagagagag 360
 Db 301 tatgtctgagagctgctctccctgctcagagagagagagagagagagagagagag 360
 QY 361 ggaagctag 420
 Db 361 ggaagctag 420
 QY 421 gaaagctcag 480
 Db 421 gaaagctcag 480
 QY 481 ctcaag 540
 Db 481 ctcaag 540
 QY 541 tctgcaatgag 600
 Db 541 tctgcaatgag 600
 QY 601 gtccttgacaacaaag 660
 Db 601 gtccttgacaacaaag 660
 QY 661 tatgtcttaatttctctgagagagagagagagagagagagagagagagagagagag 720
 Db 661 tatgtcttaatttctctgagagagagagagagagagagagagagagagagagagag 720
 QY 721 accactctgag 780
 Db 721 accactctgag 780
 QY 781 tatgtctgag 840
 Db 781 tatgtctgag 840
 QY 841 catgagacaaag 900
 Db 841 catgagacaaag 900
 QY 901 ctgataaataaagagagagctctcacttctgtatgttggatcagaagata 960
 Db 901 ctgataaataaagagagagctctcacttctgtatgttggatcagaagata 960
 QY 961 gtacagcttctacttgaagaataatataatctctcactcagaatctctgacagag 1020
 Db 961 gtacagcttctacttgaagaataatataatctctcactcagaatctctgacagag 1020
 QY 1021 gccaagagatagctgttctctgactcactcgaatttcgcaattctgactac 1080

XX	AAHQ2781;
AC	
XX	14-JUN-2001 (first entry)
XX	

DE Prostate tumour antigen determined cDNA splice variant of B305D #10
XX
KW Human; prostate tumour antigen; prostate tumour; therapy; diagnosis;
KW prostate cancer; immunogenic; cytostatic; vaccine; ss.
XX

05	Homo sapiens.
XX	
PN	W0200125272-A2
XX	

PD 12-APR-2001,
XX
PF 04-OCT-2000; 2000WO-US27464.
XX

PR 04-OCT-1999; 99US-
XX
PA (COR1-) CORIXA CORP.
XX

PI Xu J., Skelby VAW, Reed SG, Chivers MA,
XX
WPI: 2001-245062/25.
OR
D. 0000-00024017.

XX Prostate specific protein and its encoding polynucleotide, useful for
PI the treatment and diagnosis of prostate cancer -
PI
XX

PS Claim 50; page 233; 276pp; English
XX
CC The present invention describes an
00

its variant, (1) have cytostatic activity and can be used in vaccine production, (1), prostate tumour antigen polynucleotides, an antigen presenting cell (APC e.g. a dendritic cell) that expresses (1), and a

used in the exemplification of the present invention.

Query Match:	97.79;	Score 1128;	DP 22;	Length 2040;
Best Local Similarity	100.00;	Pred. No. 0;		
Matches 1128;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0

UY	1	atagatgattgaattgatttgcattgcggctgcctctctgctggaagaacgctttgaagtc	60
Dh	1	atctgatttgaagctggaattctctcctgcgcgcctgacctctctctggaagaacgatttgatctc	60
UY	61	aaatgacaaatctggacaaatatttgctgcgccttgctctccctgctgcgcgaataatgcgcga	120
Dh	61	aaagatcaaatatgggaataatggctgctctccctgctgcgcgcgaagaatggctggatg	120
UY	121	aaacacatggagactcttgaagaccacgaaggaactctgtctatgaagaacttcagaagcaag	180
Dh	121	aaacacatggagactcttgaagaccacgaaggaactctgtctatgaagaacttcagaagcaag	180
UY	181	atgaacaaatctatgcgcctccatctctccctgctctgtaaggaataatggcaagacacgtg	240
Dh	181	atgaacaaatgattgcgcgcctccatctctccctgctctgtaaggaataatgggaacacgtg	240
UY	241	gaagcttctgaagacacaaatgctctgctctatgaagaactcagaagaacaaatgggcaag	300
Dh	241	gaagcttctgaagacacaaatgctctgctctatgaagaactcagaagaacaaatgggcaag	300

[illegible]

RESULT	15
AAA06599	
ID	AAA06599; standard; cDNA; 2000 BP.
XX	
AC	AAA06599;
XX	
DT	13 JUN 2000 (first entry)
XX	
DE	Human immunogenic prostate tumour protein cDNA sequence SEQ ID NO: 374.
XX	
KW	human; prostate cancer; diagnosis; tumour; gene therapy; detection;
KW	immunogenic; cytosolic; vacuole; ss.
XX	
OS	Homo sapiens.
XX	
IN	WO200004149-A2.

•
•
•

Software version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

MATCHSCORE: matches searched, using 88 nodes

Run on: March 9, 2002, 06:06:47 : Search Time 78.94 Seconds
(with all updates)

434,942 Million cell updates/sec

Cell: 09 699 295 301

Port: 1155

Search: 1 updates/minute

Search Path: 0.1 to 100

Search: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

Match: 0.1 to 100, 0.1 to 100, 0.1 to 100

ATTACHMENTS

RESULT 1

US 09 991 789A 291/c

Sequence 291, Application US/09091789A

Patent No. 6,225,004

GENERAL INFORMATION:

Applicant: Fudakis, Tony N.

Inventor: Smith, John M.

Attorney: Fudakis, Tony N.

Address: 2001 Fifth Avenue, Suite 600

City: Seattle

State: Washington

Country: USA

Zip: 98104 7092

Computer Readable Form:

Medium Type: Floppy disk

Computer File Name: 1001

Operating System: PC DOS/MS DOS

Software: Patent to be issued #110, Version #1.1

CURRENT APPLICATION DATA:

Applicant: Fudakis, Tony N.

Inventor: Smith, John M.

Attorney: Fudakis, Tony N.

Address: 2001 Fifth Avenue, Suite 600

City: Seattle

State: Washington

Country: USA

Zip: 98104 7092

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

Sequence 14, Appl

COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC DOS/MS DOS
 SOFTWARE: Patent In Release #1.0, Version #1.40
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/422,676
 FILING DATE: 12 Dec 1998
 CLASSIFICATION:
 ALTERNATIVE INFORMATION:
 NAME: Mark, David J.
 REGISTRATION NUMBER: 41,992
 REFERENCE/WORKSHEET NUMBER: 200124, 40101
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (206) 622-4000
 TELEFAX: (206) 622-6041
 INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 607 base pairs
 TYPE: nucleotide acid
 STRANDEDNESS: single
 topology: linear
 US-09-422,676-1

Query Match 1.6K; Score 18; DB 4; Length 3877;
 Best Local Similarity 100.0%; Prod. No. 12;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0.

US 694466046A 880
 ID: 694466046A 6612

RESULT 5
 US-09-422,676-1
 Sequence 1, Application US/09/422,676
 Patent No. 610,203
 GENERAL INFORMATION:
 APPLICANT: Etkowitz, Robert Z.
 TITLE OF INVENTION: INHIBITORS OF LIZARDIN PROTEIN EXPRES
 NUMBER OF SEQUENCES: 14
 ADDRESS/INVENTOR ADDRESS:
 ADDRESS: SEED and BERRY LLP
 STREET: 6400 Columbia Court Ct., 701 Fifth Avenue
 CITY: Seattle
 STATE: Washington
 COUNTRY: USA
 ZIP: 98104 7092
 COMPUTER READABLE FORM:
 MEDIUM TYPE: floppy disk
 MEDIUM: IBM PC compatible
 OF READING SYSTEM: PC DOS/MS DOS
 SOFTWARE: Patent In Release #1.0, Version #1.40
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/422,676
 FILING DATE:
 CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US/09/211,290
 FILING DATE: 12 Dec 1998
 ALTERNATIVE INFORMATION:
 NAME: Mark, David J.
 REGISTRATION NUMBER: 41,992
 REFERENCE/WORKSHEET NUMBER: 200124, 40101
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (206) 622-4000
 TELEFAX: (206) 622-6041
 INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 607 base pairs
 TYPE: nucleotide acid
 STRANDEDNESS: single
 topology: linear
 US-09-422,676-1

Query Match 1.6K; Score 18; DB 4; Length 3877;
 Best Local Similarity 100.0%; Prod. No. 12;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

US 694466046A 880
 ID: 694466046A 6612

RESULT 6
 US-09-466-046A-1
 Sequence 1, Application US/09/466,046A
 Patent No. 628,197
 GENERAL INFORMATION:
 APPLICANT: Etkowitz, Robert Z.
 TITLE OF INVENTION: INHIBITORS OF LIZARDIN PROTEIN EXPRES
 NUMBER OF SEQUENCES: 14
 ADDRESS/INVENTOR ADDRESS:
 ADDRESS: SEED and BERRY LLP
 STREET: 6400 Columbia Court Ct., 701 Fifth Avenue
 CITY: Seattle
 STATE: Washington
 COUNTRY: USA
 ZIP: 98104 7092
 COMPUTER READABLE FORM:
 MEDIUM TYPE: floppy disk
 MEDIUM: IBM PC compatible
 OPERATING SYSTEM: PC DOS/MS DOS
 SOFTWARE: Patent In Release #1.0, Version #1.40
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/466,046A
 FILING DATE: 17 Dec 2001
 CLASSIFICATION: unknown
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US/09/211,290
 FILING DATE: unknown
 ALTERNATIVE INFORMATION:
 NAME: Mark, David J.
 REGISTRATION NUMBER: 41,992
 REFERENCE/WORKSHEET NUMBER: 200124, 40101
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (206) 622-4000
 TELEFAX: (206) 622-6041
 INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 4877 base pairs
 TYPE: nucleotide acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 SEQUENCE DESCRIPTION: SEQ ID NO: 1:
 US-09-466-046A-1

Query Match 1.6K; Score 18; DB 4; Length 3877;
 Best Local Similarity 100.0%; Prod. No. 12;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

US 694466046A 880
 ID: 694466046A 6612

RESULT 7
 US-09-564-496A-18
 Sequence 18, Application US/09/564,966A
 Patent No. 602,2687
 GENERAL INFORMATION:
 APPLICANT: Lottato, Michelle
 APPLICANT: Mark, Douglas A.
 APPLICANT: McAllister, Kimberly
 TITLE OF INVENTION: DIAGNOSTICS OF AND THERAPY FOR

```

1 TITLE OF INVENTION: HEREDITARY HAEMOPHAGIC TELANGIECTASIA
2 NUMBER OF SEQUENCES: 42
3 CORRESPONDENCE ADDRESS:
4 ADDRESSEE: Fish & Richardson P.C.
5 STREET: 225 Franklin Street
6 CITY: Boston
7 STATE: MA
8 COUNTRY: USA
9 ZIP: 02110-2804
10 COMPUTER READABLE FORM:
11 MEDIUM TYPE: Diskette
12 OPERATING SYSTEM: Windows 95
13 SOFTWARE: FASTSU for Windows Version 2.0b
14 CURRENT APPLICATION DATA:
15 APPLICATION NUMBER: US/98/564,496C
16 FILING DATE: 29-NOV-1995
17 PRIORITY APPLICATION DATA:
18 APPLICATION NUMBER: 08/346,129
19 FILING DATE: 29-NOV-1994
20 ATTORNEY/AGENT INFORMATION:
21 NAME: Fraser, Janis K.
22 REGISTRATION NUMBER: 34,819
23 REFERENCE/RELATED NUMBERS: 06765/000001
24 TELEPHONE: 617/542-5070
25 TELEFAX: 617/542-8906
26 TELEEX: 200154
27 INFORMATION FOR SEQ ID NO: 18:
28 SEQUENCE CHARACTERISTICS:
29 LENGTH: 654 base pairs
30 TYPE: nucleic acid
31 STRANDEDNESS: double
32 TOPOLOGY: linear
33 MOLECULE TYPE: Genomic DNA
34 US-08-564-496C-18
35
36 Query Match 1.5%; Score 17; DB 3; Length 654;
37 Best Local Similarity 100.0%; Pred. No. 34;
38 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
39
40 QY 479 tgcctagagagactgac 495
41 |||||||||||||||
42 Db 108 tgcctagagagactgac 124
43
44 RESULT 8
45 PCT-US95-15428-18
46 Sequence 18, Application PC/TUS9515428
47 GENERAL INFORMATION:
48 APPLICANT: Letatier, Michelle
49 APPLICANT: Marchuk, Douglas A.
50 APPLICANT: McAllister, Kimberly
51 TITLE OF INVENTION: DIAGNOSTIC AND THERAPY FOR
52 TITLE OF INVENTION: HEREDITARY HAEMOPHAGIC TELANGIECTASIA
53 NUMBER OF SEQUENCES: 41
54 CORRESPONDENCE ADDRESS:
55 ADDRESSEE: Fish & Richardson P.C.
56 STREET: 225 Franklin Street Suite 3100
57 CITY: Boston
58 STATE: Massachusetts
59 COUNTRY: U.S.A.
60 ZIP: 02110-2804
61 COMPUTER READABLE FORM:
62 MEDIUM TYPE: Floppy disk
63 OPERATING SYSTEM: PC-DOS/MS-DOS
64 SOFTWARE: Patcutin Release #1.0, Version #1.30B
65 CURRENT APPLICATION DATA:
66 APPLICATION NUMBER: PC/TUS95/15428
67 FILING DATE: 29-NOV-1995
68 PRIORITY APPLICATION DATA:

```

```

1 APPLICATION NUMBER: 08/346,129
2 FILING DATE: 29-NOV-1994
3 ATTORNEY/AGENT INFORMATION:
4 NAME: Fraser, Janis K.
5 REGISTRATION NUMBER: 34,819
6 REFERENCE/RELATED NUMBER: 06765/000001
7 TELECOMMUNICATION INFORMATION:
8 TELEPHONE: 617/542-5070
9 TELEFAX: 617/542-8906
10 TELEEX: 200154
11 INFORMATION FOR SEQ ID NO: 18:
12 SEQUENCE CHARACTERISTICS:
13 LENGTH: 656 base pairs
14 TYPE: nucleic acid
15 STRANDEDNESS: double
16 TOPOLOGY: linear
17 MOLECULE TYPE: DNA (genomic)
18 PCT-US95-15428-18
19
20 Query Match 1.5%; Score 17; DB 5; Length 656;
21 Best Local Similarity 100.0%; Pred. No. 34;
22 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
23
24 QY 479 tgcctagagagactgac 495
25 |||||||||||||||
26 Db 111 tgcctagagagactgac 127
27
28 RESULT 9
29 US 08 650 129 1/c
30 Sequence 1, Application US/08650129
31 Patent No. 5747322
32 GENERAL INFORMATION:
33 APPLICANT: Tsui, Christopher A.
34 TITLE OF INVENTION: Recombinant Crab Collagenase
35 NUMBER OF SEQUENCES: 6
36 CORRESPONDENCE ADDRESS:
37 ADDRESSEE: Majestic Parsons Siebert & Hsue
38 STREET: Four Embarcadero Center, Suite 1450
39 CITY: San Francisco
40 STATE: CA
41 COUNTRY: USA
42 ZIP: 94111-4121
43 COMPUTER READABLE FORM:
44 MEDIUM TYPE: Floppy disk
45 OPERATING SYSTEM: PC-DOS/MS-DOS
46 SOFTWARE: Patcutin Release #1.0, Version #1.30
47 CURRENT APPLICATION DATA:
48 APPLICATION NUMBER: 08/650,129
49 FILING DATE: 09-MAY-1996
50 CLASSIFICATION: 435
51 ATTORNEY/AGENT INFORMATION:
52 NAME: Siebert, J. Suzanne
53 REGISTRATION NUMBER: 28,758
54 REFERENCE/RELATED NUMBER: 3500 084050
55 TELECOMMUNICATION INFORMATION:
56 TELEPHONE: (415) 362-5556
57 TELEFAX: (415) 362-5418
58 INFORMATION FOR SEQ ID NO: 1:
59 SEQUENCE CHARACTERISTICS:
60 LENGTH: 734 base pairs
61 TYPE: nucleic acid
62 STRANDEDNESS: single
63 TOPOLOGY: linear
64 MOLECULE TYPE: cDNA
65 US-08-650-129-1
66
67 Query Match 1.5%; Score 17; DB 1; Length 734;
68 Best Local Similarity 100.0%; Pred. No. 35;

```


Host Local Similarity 100.0% Prod. No. 472
Matches 172 Conservation 0% Mismatches 0% Indels 0% Gaps 0%
Seq 104 cctcttctggaacacga 1120
|||||
10 cctcttctggaacacga 504

Search completed: March 9, 2002, 04:13:14
Job Time: 0087.300

•
•
•

480	601	721	841	961
481	602	722	842	962
482	603	723	843	963
483	604	724	844	964
484	605	725	845	965
485	606	726	846	966
486	607	727	847	967
487	608	728	848	968
488	609	729	849	969
489	610	730	850	970
490	611	731	851	971
491	612	732	852	972
492	613	733	853	973
493	614	734	854	974
494	615	735	855	975
495	616	736	856	976
496	617	737	857	977
497	618	738	858	978
498	619	739	859	979
499	620	740	860	980
500	621	741	861	981
501	622	742	862	982
502	623	743	863	983
503	624	744	864	984
504	625	745	865	985
505	626	746	866	986
506	627	747	867	987
507	628	748	868	988
508	629	749	869	989
509	630	750	870	990
510	631	751	871	991
511	632	752	872	992
512	633	753	873	993
513	634	754	874	994
514	635	755	875	995
515	636	756	876	996
516	637	757	877	997
517	638	758	878	998
518	639	759	879	999
519	640	760	880	1000
520	641	761	881	1001
521	642	762	882	1002
522	643	763	883	1003
523	644	764	884	1004
524	645	765	885	1005
525	646	766	886	1006
526	647	767	887	1007
527	648	768	888	1008
528	649	769	889	1009
529	650	770	890	1010
530	651	771	891	1011
531	652	772	892	1012
532	653	773	893	1013
533	654	774	894	1014
534	655	775	895	1015
535	656	776	896	1016
536	657	777	897	1017
537	658	778	898	1018
538	659	779	899	1019
539	660	780	900	1020
540	661	781	901	1021
541	662	782	902	1022
542	663	783	903	1023
543	664	784	904	1024
544	665	785	905	1025
545	666	786	906	1026
546	667	787	907	1027
547	668	788	908	1028
548	669	789	909	1029
549	670	790	910	1030
550	671	791	911	1031
551	672	792	912	1032
552	673	793	913	1033
553	674	794	914	1034
554	675	795	915	1035
555	676	796	916	1036
556	677	797	917	1037
557	678	798	918	1038
558	679	799	919	1039
559	680	800	920	1040
560	681	801	921	1041
561	682	802	922	1042
562	683	803	923	1043
563	684	804	924	1044
564	685	805	925	1045
565	686	806	926	1046
566	687	807	927	1047
567	688	808	928	1048
568	689	809	929	1049
569	690	810	930	

RESULTS

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

AX1005934

<

[illegible]

```

Db 901 CTGATAGATATGGAAGAGTGTCTCACTACTGCTATCTTTGGCAAGCAAGTATA 960
Gy 961 GTGAGCTTCTACTTGAAGAAATATTATATATCTTCTCAAGATCTATCTTGGAGAG 1020
Db 961 GTAGAGTCTTCTACTTGAAGAAATATTATATATCTTCTCAAGAGTATCTTGGAGAG 1020
Gy 1021 GCGAGAGATATGCTCTTCTTATCATATATCAAGTATATATATATATCTTGGAGAG 1080
Db 1021 GCGAGAGATATGCTCTTCTTATCATATATCAAGTATATATATATATCTTGGAGAG 1080
Gy 1081 AAAAAGAAAGAGATGCTTAAATCTCTTCTTAAACAGCAATCTCAAGCAAGACTTAA 1138
Db 1081 AAAAAGAAAGAGATGCTTAAATCTCTTCTTAAACAGCAATCTCAAGCAAGACTTAA 1138

RESULT 4
AX140884 2000 bp DNA PAT 31-MAY-2001
DEFINITION Sequence 374 from Patent WO0134802.
ACCESSION AX140884
VERSION AX140884.1 GI:14280987
KEYWORDS
SOURCE
ORGANISM human.
REFERENCE
Mammalia; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
1 (bases 1 to 2000)
Xu, J., Dillon, D. C., Mitcham, J. L., Harlocker, S. L., Jiang, Y.,
Reed, S. G., Kalos, M. D., Reller, M. W., Stolk, J. A., Day, C. H.,
Skeiky, Y. A. and Wang, A.
Compositions and methods for the therapy and diagnosis of prostate
cancer.
Patent: WO 0134802 A 374 17-MAY-2001;
JOURNAL
CORIXA CORPORATION (US)
FEATURES
Location/Qualifiers
source 1..2000
/organism="Homo sapiens"
/db_xref="taxon:9606"
BASE COUNT 698 a 388 c 489 g 425 t
ORIGIN

Query Match 98.0%, Score 1131.6; DB 6; Length 2000;
Best Local Similarity 99.4%; Prod. No. 1; E 277;
Matches 1134; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Gy 1 acgctgattgaagttgattctatgacgagctgctctctctctctctctctctctctc 60
Db 1 ATGCTGCTTGAAGTTGATTCTATGCGGCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 60
Gy 61 aaggaagagatgagcaatgattgttgccttgcctctctctctctctctctctctctctc 120
Db 61 AAGGAGAGATGAGCAATGATTGTTCCTTGCCTCTCTCTCTCTCTCTCTCTCTCTCTCT 120
Gy 121 aagcaatgagcaatgagcaatgagcaatgagcaatgagcaatgagcaatgagcaatgag 180
Db 121 AAGCAATGAGCAATGAGCAATGAGCAATGAGCAATGAGCAATGAGCAATGAGCAATGAG 180
Gy 181 aagcaatgagcaatgagcaatgagcaatgagcaatgagcaatgagcaatgagcaatgag 240
Db 181 AAGCAATGAGCAATGAGCAATGAGCAATGAGCAATGAGCAATGAGCAATGAGCAATGAG 240
Gy 241 aagcaatgagcaatgagcaatgagcaatgagcaatgagcaatgagcaatgagcaatgag 300
Db 241 AAGCAATGAGCAATGAGCAATGAGCAATGAGCAATGAGCAATGAGCAATGAGCAATGAG 300
Gy 301 aagcaatgagcaatgagcaatgagcaatgagcaatgagcaatgagcaatgagcaatgag 360
Db 301 AAGCAATGAGCAATGAGCAATGAGCAATGAGCAATGAGCAATGAGCAATGAGCAATGAG 360
Gy 361 aagcaatgagcaatgagcaatgagcaatgagcaatgagcaatgagcaatgagcaatgag 420
Db 361 AAGCAATGAGCAATGAGCAATGAGCAATGAGCAATGAGCAATGAGCAATGAGCAATGAG 420

```

```

Db 361 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 420
Gy 421 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 480
Db 421 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 480
Gy 481 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 540
Db 481 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 540
Gy 541 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 600
Db 541 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 600
Gy 601 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 660
Db 601 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 660
Gy 661 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 720
Db 661 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 720
Gy 721 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 780
Db 721 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 780
Gy 781 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 840
Db 781 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 840
Gy 841 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 900
Db 841 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 900
Gy 901 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 960
Db 901 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 960
Gy 961 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1020
Db 961 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1020
Gy 1021 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1080
Db 1021 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1080
Gy 1081 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1138
Db 1081 GAGCACTAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1138

RESULT 5
AX106594 2040 bp DNA PAT 40-APR-2001
DEFINITION Sequence 375 from Patent WO0125272.
ACCESSION AX106594
VERSION AX106594.1 GI:13922265
KEYWORDS
SOURCE
ORGANISM human.
REFERENCE
Mammalia; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
1 (bases 1 to 2040)
Xu, J., Skeiky, Y. A., Reed, S. G., and Cheever, M. A.
Compositions and methods for the therapy and diagnosis of prostate
cancer.
Patent: WO 0125272 A 375 12-APR-2001;
JOURNAL
CORIXA CORPORATION (US)
FEATURES
Location/Qualifiers
source 1..2040
/organism="Homo sapiens"
/db_xref="taxon:9606"
BASE COUNT 716 a 392 c 500 g 432 t

```


[illegible]

[illegible]

RESULT 10	AR148112/c	AR148112	1851 bp	CNN	PAT	08-AUG-2001
LOCUS		Sequence 291	from patent US 6,226,054.			
DEFINITION		AR148112				
ACCESSION		AR148112.1	GI:15112202			
VERSION						
KEYWORDS						
STRAINS						
ORGANISM		UNKNOWN				

REFERENCE	UNCLASSIFIED
1 (bases 1 to 1851)	
FRIDKIS, T. N., SMITH, J. M. and PEEL, S. G.	
TITLE	Compositions and methods for the treatment and diagnosis of breast cancer
JOURNAL	Patent: US 6,290,054 A 291.01 MAY 2001;
FEATURES	Location/Qualifiers
SOURCE	1. 1851
BASE COUNT	474 a /organism "unknown" 536 t 1 others
ORIGIN	474 a 460 c 380 q

Query Match	71.8%	Score 929, DB 6, Length 1651,
Best Local Similarity	95.1%	Prod. No. 3,70-200;
Misaligns	878, Corrected to	6, Misaligns 40, Indels 2

[illegible]

[illegible]

circles were made *in vitro* following HAP amplification, this DNA was used as tracer in a sub+reactive hybridization

```

reaction. The driver was PCR-amplified cDNAs from a pool
of 5,000 clones made from the same library (clones
985608-986759, 1101192-1101959, and 1227929-1228615).
Subtraction by Bento Scores and M. Fatima Bonafide.
a      79 c      91 q      153 t
12.1%; Score 140; DB 10; Length 451;
ity 100.0%, Pctd. No. 4,3e 62,
servative 0; Mismatches 0; Indels 0; Gaps 0;
ttatattcgtatgatatgatgaagaalatalagcaacctactt 975
tttgatgtagtctctatctctctctctctctctctctctctct
tttatgtalettcacagatctatctggacacgcacaaataatqet 1035
ATGAGTGTATTCTTCCTCAAGACTATTTGGACAGAGCAGCATAGT 166
atccatcat 1055
|||||
ATCATCATCT 186
531 bp DNA GSS 15-JUN-1999
BBL_GOL_17A_RPCT-11 Human Male BAC Library Homo sapiens
clone Plate=720 Col=1 Row=N, DNA sequence.
.. GI:5076753
iens
Mammalia: Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Actinopteri; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
(GenBank accession #U00001.1)
(GenBank accession #U00001.1) Smith K. Swartzell S. Holzman T.
Shaker R. Furukawa Y. Zhao S. Adams M.D. and
the human genome
The human genome
tagged connectors: A sequence approach to mapping and
the human genome
Metzger W. A. (1999) 374-344 (1999)
Maharaj O.S., Wallace J.C., Hood L.
Output Sequencing Center
University of Washington
1000 Anne Avenue North, Seattle, WA 98199, USA
(6) 616-3618
(5) 616-3887
wallace@u.washington.edu
the driver derived from the human BAC library RPCT-11. For BAC
availability, please contact Pieter de Jong
deJong@mol.biology.mcgill.ca). Clones may be purchased from
BioLabs (http://bio.labs.com) or other vendors (see http://
Resistor h Genetics (info@resistorh.com) BAC end Web Server:
www.hisc.washington.edu
20 row; N column; 1
ert: 17
AC ends
ility sequence stop: 531.
location/Qualifiers
1..531
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="Plate=720 Col=1 Row=N"
/clone_id="RPCT_11 Human Male BAC Library"
/sec="male"
Note "Vector, pBAD33, Site_1, EcoRI, Site_2, EcoRI;
Male blood DNA was isolated from one randomly chosen donor
and partially digested with a combination of EcoRI and
SmaI. Multiple size selected DNA was cloned into the
```


BASE SEQUENCE		Phylogenetic position of "Ecopol sites"		11 others	
Site	Base	9.2	9.2	9.9	11 others
Ecopol Site 1	11.2%	Site 1	1.2%	Site 1	1.2%
Ecopol Site 2	10.0%	Site 2	1.0%	Site 2	1.0%
Ecopol Site 3	9.2%	Site 3	0.9%	Site 3	0.9%
Ecopol Site 4	8.4%	Site 4	0.8%	Site 4	0.8%
Ecopol Site 5	7.6%	Site 5	0.7%	Site 5	0.7%
Ecopol Site 6	6.8%	Site 6	0.6%	Site 6	0.6%
Ecopol Site 7	6.0%	Site 7	0.5%	Site 7	0.5%
Ecopol Site 8	5.2%	Site 8	0.4%	Site 8	0.4%
Ecopol Site 9	4.4%	Site 9	0.3%	Site 9	0.3%
Ecopol Site 10	3.6%	Site 10	0.2%	Site 10	0.2%
Ecopol Site 11	2.8%	Site 11	0.1%	Site 11	0.1%
Ecopol Site 12	2.0%	Site 12	0.0%	Site 12	0.0%
Ecopol Site 13	1.2%	Site 13	0.0%	Site 13	0.0%
Ecopol Site 14	0.4%	Site 14	0.0%	Site 14	0.0%
Ecopol Site 15	0.0%	Site 15	0.0%	Site 15	0.0%
Ecopol Site 16	0.0%	Site 16	0.0%	Site 16	0.0%
Ecopol Site 17	0.0%	Site 17	0.0%	Site 17	0.0%
Ecopol Site 18	0.0%	Site 18	0.0%	Site 18	0.0%
Ecopol Site 19	0.0%	Site 19	0.0%	Site 19	0.0%
Ecopol Site 20	0.0%	Site 20	0.0%	Site 20	0.0%
Ecopol Site 21	0.0%	Site 21	0.0%	Site 21	0.0%
Ecopol Site 22	0.0%	Site 22	0.0%	Site 22	0.0%
Ecopol Site 23	0.0%	Site 23	0.0%	Site 23	0.0%
Ecopol Site 24	0.0%	Site 24	0.0%	Site 24	0.0%
Ecopol Site 25	0.0%	Site 25	0.0%	Site 25	0.0%
Ecopol Site 26	0.0%	Site 26	0.0%	Site 26	0.0%
Ecopol Site 27	0.0%	Site 27	0.0%	Site 27	0.0%
Ecopol Site 28	0.0%	Site 28	0.0%	Site 28	0.0%
Ecopol Site 29	0.0%	Site 29	0.0%	Site 29	0.0%
Ecopol Site 30	0.0%	Site 30	0.0%	Site 30	0.0%
Ecopol Site 31	0.0%	Site 31	0.0%	Site 31	0.0%
Ecopol Site 32	0.0%	Site 32	0.0%	Site 32	0.0%
Ecopol Site 33	0.0%	Site 33	0.0%	Site 33	0.0%
Ecopol Site 34	0.0%	Site 34	0.0%	Site 34	0.0%
Ecopol Site 35	0.0%	Site 35	0.0%	Site 35	0.0%
Ecopol Site 36	0.0%	Site 36	0.0%	Site 36	0.0%
Ecopol Site 37	0.0%	Site 37	0.0%	Site 37	0.0%
Ecopol Site 38	0.0%	Site 38	0.0%	Site 38	0.0%
Ecopol Site 39	0.0%	Site 39	0.0%	Site 39	0.0%
Ecopol Site 40	0.0%	Site 40	0.0%	Site 40	0.0%
Ecopol Site 41	0.0%	Site 41	0.0%	Site 41	0.0%
Ecopol Site 42	0.0%	Site 42	0.0%	Site 42	0.0%
Ecopol Site 43	0.0%	Site 43	0.0%	Site 43	0.0%
Ecopol Site 44	0.0%	Site 44	0.0%	Site 44	0.0%
Ecopol Site 45	0.0%	Site 45	0.0%	Site 45	0.0%
Ecopol Site 46	0.0%	Site 46	0.0%	Site 46	0.0%
Ecopol Site 47	0.0%	Site 47	0.0%	Site 47	0.0%
Ecopol Site 48	0.0%	Site 48	0.0%	Site 48	0.0%
Ecopol Site 49	0.0%	Site 49	0.0%	Site 49	0.0%
Ecopol Site 50	0.0%	Site 50	0.0%	Site 50	0.0%
Ecopol Site 51	0.0%	Site 51	0.0%	Site 51	0.0%
Ecopol Site 52	0.0%	Site 52	0.0%	Site 52	0.0%
Ecopol Site 53	0.0%	Site 53	0.0%	Site 53	0.0%
Ecopol Site 54	0.0%	Site 54	0.0%	Site 54	0.0%
Ecopol Site 55	0.0%	Site 55	0.0%	Site 55	0.0%
Ecopol Site 56	0.0%	Site 56	0.0%	Site 56	0.0%
Ecopol Site 57	0.0%	Site 57	0.0%	Site 57	0.0%
Ecopol Site 58	0.0%	Site 58	0.0%	Site 58	0.0%
Ecopol Site 59	0.0%	Site 59	0.0%	Site 59	0.0%
Ecopol Site 60	0.0%	Site 60	0.0%	Site 60	0.0%
Ecopol Site 61	0.0%	Site 61	0.		

[illegible]

REFERENCE 1 (bases 1 to 380)
 AUTHORS Mammalia: Eutheria; Primates: Catarrhini; Homnidae: Homo.
 Dias Neto, E., Garcia Corrêa, R., Verjowski-Almeida, S., Brites, M. P., Nagai, M. A., da Silva, W. Jr., Zago, M. A., Bordin, S., Costa, F. F., Goldman, G. H., Carvalho, A. P., Matsukuma, A., Bala, G. S., Simpson, A. H., Brunstein, A., de Oliveira, P. S., Bucher, P., Jongeneel, C. V., O'Hare, M. J., Soares, F., Brentani, R. R., Reis, L. F., de Souza, S. J., and Simpson, A. J.

TITLE Shotgun sequencing of the human transcriptome with ORF expressed sequence tags
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 97 (7): 3491-3496 (2000)
 MEDLINE 2002663
 COMMENT Contact: Simpson A.J.G., Laboratory of Cancer Genetics, Ludwig Institute for Cancer Research, Rua Prof. Antonio Prudente 109, 4 andar, 01502-010, São Paulo-SP, Brazil
 Tel: +55-11-2704922
 Fax: +55-11-2707001
 Email: asimpson@ludwig.org.br
 This sequence was derived from the FAPESP/LICP Human Cancer Genome Project. This entry can be seen in the following URL: (<http://www.ludwig.org.br/scripts/genetlm2.pl?cl=612-CM1-BT0397-201>)
 Seq primer: puc 18 forward
 High quality sequence start: 99
 High quality sequence stop: 379.
 Location/Qualifiers
 1..380

FEATURES
 source
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone_lib="BNC0276"
 /dev_stage="Adult"
 /note="Organ: breast; normal; Vector: puc18; Site: 1; Smat: Site 2; Smat: A mini-library was made by cloning products derived from GRESFES PCR (U.S. Letters Patent application No. 196,716 - Ludwig Institute for Cancer Research) profiles into the pUC 18 vector. Reverse transcription of tissue mRNA and cDNA amplification were performed under low stringency conditions."
 BASE COUNT
 80 a 106 c 109 g 85 t
 ORIGIN

Query Match 4.5%, Score 52, DB 11, Length 380;
 Best Local Similarity 100.0%; Prod. No 5.4e-16;
 Matches 52; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 7
 LOCUS AO372700
 DEFINITION RFL11-14712.TJ RFL1-11 Homo sapiens genomic clone RFL1 11 14712.
 DNA Sequence:
 ACCESSION AO372700
 VERSION AO372700.1 GI:1443723
 KEYWORDS GSS.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae: Homo.
 REFERENCES
 1 (bases 1 to 592)
 Zhao, S., Adams, M. D., Nierman, W., Malek, J., de Jong, P., and Webster, J. C.

TITLE Use of PAC End Sequences from Library RFL1-11 for Sequence Ready Map Building
 JOURNAL Map Building (1997)
 MEDLINE 9070335
 COMMENT Contact: Shaying Zhao, William Nierman, Mark Adams

Department of Eukaryotic Genomics
 The Institute for Genomic Research
 9710 Medical Center Dr., Rockville, MD 20850
 Tel: 301 938 0200
 Fax: 301 938 0208
 Email: hbeet@igc.org
 Clones are derived from the human BAC library RFL1-11. For BAC library availability, please contact Peter de Jong (pietor@igc.med.buffalo.edu). Clones may be purchased from BACPAC Resources (<http://bacpac.med.buffalo.edu/bacpac/>) or from Research Genetics (<http://genetics.com>). BAC end search page: <http://www.igc.org/igc1/bacend/bacend.html>
 Seq primer: SP6
 Class: BAC ends.
 Location/Qualifiers
 1..592
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /db_xref="taxon:9606"
 /clone_lib="RFL1-11-14712"
 /clone_lib="RFL1-11"
 /sex="Male"
 /cell_type="lymphocytes"
 /note="Vector: pBAC3.6; Site: 1; EukR; Site 2: EukR; RFL11 Human Male BAC library"
 BASE COUNT
 199 a 87 c 99 g 207 t
 ORIGIN

Query Match 4.3%, Score 50, DB 13, Length 592;
 Best Local Similarity 100.0%; Prod. No. 6.1e-15;
 Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 8
 LOCUS BE069869
 DEFINITION CMI 310397 201239-073 d11 R10397 Homo sapiens cDNA, mRNA sequence.
 ACCESSION BE069869
 VERSION BE069869.1 GI:8414519
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae: Homo.
 REFERENCES
 1 (bases 1 to 187)
 Dias Neto, E., Garcia Corrêa, R., Verjowski-Almeida, S., Brites, M. R., Nagai, M. A., da Silva, W. Jr., Zago, M. A., Bordin, S., Costa, F. F., Goldman, G. H., Carvalho, A. P., Matsukuma, A., Bala, G. S., Simpson, A. H., Brunstein, A., de Oliveira, P. S., Bucher, P., Jongeneel, C. V., O'Hare, M. J., Soares, F., Brentani, R. R., Reis, L. F., de Souza, S. J., and Simpson, A. J.

TITLE Shotgun sequencing of the human transcriptome with ORF expressed sequence tags
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 97 (7): 3491-3496 (2000)
 MEDLINE 2002663
 COMMENT Contact: Simpson A.J.G., Laboratory of Cancer Genetics, Ludwig Institute for Cancer Research, Rua Prof. Antonio Prudente 109, 4 andar, 01502-010, São Paulo-SP, Brazil
 Tel: +55-11-2704922
 Fax: +55-11-2707001
 Email: asimpson@ludwig.org.br
 This sequence was derived from the FAPESP/LICP Human Cancer Genome Project. This entry can be seen in the following URL: (<http://www.ludwig.org.br/scripts/genetlm2.pl?cl=612-CM1-BT0397-201>)
 Seq primer: puc 18 forward

Sat Mar 9 09:57:22 2002

us-09-699-295-301.rst

Page 8

[illegible][illegible]

	Matches	b1: Conservative	0: Mismatches	4: Indels	0: Gaps	0
QY	34	TTTTTTTGAAGAACTTGTCTGGAGAGAGATGATGAATTGTTCTGGCTTGG	94			
Db	256	TCTTCTGGAGAAATCTATTGCTTCTTCAGAGCAAGATGGGTAATGGTCTGGCTTGG	315			
QY	94	TTCTCTCTCTGCAAGAGAGAGAGAGAGAGAGATGATGATCTCTGAGAGAGAGAG	154			
Db	316	TTCTCTCTCTCTGCAAGAGAGAGAGAGAGAGAGATGATGATCTCTGAGAGAGAGAG	376			
QY	154	TTCTCTCTCTGAGAGAGAGAGAGAGAGAGATGATGATCTCTGAGAGAGAGAG	214			
Db	376	TTCTCTCTCTGAGAGAGAGAGAGAGAGAGATGATGATCTCTGAGAGAGAGAG	436			
QY	214	TTCTCTCTCTGAGAGAGAGAGAGAGAGATGATGATCTCTGAGAGAGAGAG	274			
Db	436	TTCTCTCTCTGAGAGAGAGAGAGAGAGATGATGATCTCTGAGAGAGAGAG	496			
QY	274	TTCTCTCTCTGAGAGAGAGAGAGAGAGATGATGATCTCTGAGAGAGAGAG	334			
Db	496	TTCTCTCTCTGAGAGAGAGAGAGAGAGATGATGATCTCTGAGAGAGAGAG	556			
QY	334	TTCTCTCTCTGAGAGAGAGAGAGAGAGATGATGATCTCTGAGAGAGAGAG	394			
Db	556	TTCTCTCTCTGAGAGAGAGAGAGAGAGATGATGATCTCTGAGAGAGAGAG	616			
QY	394	TTCTCTCTCTGAGAGAGAGAGAGAGAGATGATGATCTCTGAGAGAGAGAG	454			
Db	616	TTCTCTCTCTGAGAGAGAGAGAGAGAGATGATGATCTCTGAGAGAGAGAG	676			
QY	454	TTCTCTCTCTGAGAGAGAGAGAGAGAGATGATGATCTCTGAGAGAGAGAG	514			
Db	676	TTCTCTCTCTGAGAGAGAGAGAGAGAGATGATGATCTCTGAGAGAGAGAG	736			
QY	514	TTCTCTCTCTGAGAGAGAGAGAGAGAGATGATGATCTCTGAGAGAGAGAG	574			
Db	736	TTCTCTCTCTGAGAGAGAGAGAGAGAGATGATGATCTCTGAGAGAGAGAG	796			
QY	574	TTCTCTCTCTGAGAGAGAGAGAGAGAGATGATGATCTCTGAGAGAGAGAG	634			
Db	796	TTCTCTCTCTGAGAGAGAGAGAGAGAGATGATGATCTCTGAGAGAGAGAG	856			
QY	634	TTCTCTCTCTGAGAGAGAGAGAGAGAGATGATGATCTCTGAGAGAGAGAG	694			
Db	856	TTCTCTCTCTGAGAGAGAGAGAGAGAGATGATGATCTCTGAGAGAGAGAG	916			
QY	694	TTCTCTCTCTGAGAGAGAGAGAGAGAGATGATGATCTCTGAGAGAGAGAG	728			
Db	916	TTCTCTCTCTGAGAGAGAGAGAGAGAGATGATGATCTCTGAGAGAGAGAG	950			
RESULT	8					
AX140878	AX140878	1512 bp	DNA	PAT	31-MAY-2001	
LOCUS	Sequence 368 from Patent WO0134802.					
DEFINITION	AX140878					
ACCESSION	AX140878.1	GI:14280981				
VERSION						
KEYWORDS						
SOURCE						
ORGANISM	human.					
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;					
	Mammalia; Eulimeta; Primates; Catarrhini; Hominiidae; Homo.					
REFERENCE	1 (bases 1 to 1512)					
AUTHORS	Xu, L., Dillon, P. C., Mitham, N. I., Harbeck, S. L., Jiang, Y.,					
	Reed, S. G., Kalous, M. D., Fothergill, M. W., Stokke, J. A., Day, C. H.,					
	Shekly, Y. A. and Wang, A.					
TITLE	Compositions and methods for the therapy and diagnosis of prostate					
JOURNAL	cancer					
	Patent: WO 0134802-A 368 17-MAY-2001;					
FEATURES	CORONA CORPORATION (US)					
	location/Qualifiers					
SOURCE	1..1512					
	/organism="Homo sapiens"					

RESULT 11

US 09 065 474 46

Sequence 46, Application US/0906474

Patient No. 606509

GENERAL INFORMATION:

APPLICANT: Taro, Ltd.

APPLICANT: Hiroko, E. Sood

TITLE OF INVENTION: PROTEIN-LIKE AND PROTEIN-ANALOG

TITLE OF INVENTION: PROTEINS, NOVELLY ACID MOLECULES, AND

TITLE OF INVENTION: USES THEREOF

NUMBER OF INVENTIONS: 171

ADDRESS: ADDRESS:

ADDRESS: Carol Takikawa, Vets., Ph.D.

ADDRESS: Hiroko Corporation

STREET: 1825 Sharp Point Drive

CITY: Fort Collins

STATE: Colorado

COUNTRY: USA

ZIP: 80525

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

CONTAINER: 100 per computer

OPERATING SYSTEM: Windows 95

SOFTWARE: WordPerfect for Windows, Version 7.0

CURRENT APPLICATION DATA:

APPLICANT NUMBER: 09/065 474

FILING DATE: 24 Apr 1998

CLASSIFICATION:

ALTERNATIVE/INFORMATION:

NAME: Vets., Carol Takikawa

REGISTRATION NUMBER: 47459

REFERENCE/WORK ITEM NUMBER: 10 5 01

TELEPHONE: 970/494 7272

TELEFAX: 970/494 9505

INFORMATION FOR SEQ ID NO: 46

SEQUENCE CHARACTERISTICS:

LENGTH: 925 nucleotides

TYPE: nucleotide acid

STRANDEDNESS: single

SEQUENCE: linear

MEDIUM TYPE: CDMA

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

US 09 065 474 46

QY 1003 gatctatctgacacagcagcaqatatact 1035
 DB 2169 AGGAAGCAGGATATACCGCTTACATCTGCT 2201

RESULT 15

US-08-847-429A-14/c

Sequence 34, Application US/08847429A

Patent No. 5827692

GENERAL INFORMATION:

APPLICANT: Tang, Liang

APPLICANT: Helm, E. Scot

TITLE OF INVENTION: DIPEPTIDYLAMINO AND BRODIA ANKYRIN

TITLE OF INVENTION: PROTEINS, NUCLEIC ACID MOLECULES, AND

NUMBER OF INVENTION: US/08847429A

NUMBER OF SEQUENCES: 85

CORRESPONDENCE ADDRESS:

ADDRESSEE: Carol Talkington Versor, Ph.D.

ADDRESS: Heskia Corporation

CITY: Fort Collins

STATE: Colorado

COUNTRY: USA

ZIP: 80525

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: Windows 95

SOFTWARE: WordPerfect for Windows, Version 7.0

CURRENT APPLICATION DATA:

FILING DATE: 24-Apr-1997

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Versor, Carol Talkington

REGISTRATION NUMBER: 37/459

REFERENCE/DOCKET NUMBER: HW-5

TELECOMMUNICATION INFORMATION:

TELEPHONE: 970/484-9505

TELEFAX: 970/484-9505

INFORMATION FOR SEQ ID NO: 34:

SEQUENCE CHARACTERISTICS:

LENGTH: 5503 nucleotides

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: cDNA

US-08-847-429A-14

Query Match: 7.2%; Score: 92.6; DB: 1; Length: 5503;

First Local Similarity: 47.6%; Pred. No. 2.9e-14;

Matches: 244; Conservative: 0; Mismatches: 259; Indels: 0, Gaps: 0;

QY 523 actgctctacatctgagctctgcaacatgagatcgaagatgaagaactctctgagac 582
 DB 3815 ATGGCGTTGGCATTTAGCTTGCATAGATGCAATTTTGGCTGGCGAATCATTTGCTAGAA 3756

QY 583 aaagcaatitaaatgactgactatagatatagaagagactctctatcttctatct 642
 DB 3765 CAGAGAGACCGGTTGATTCAGAGCAGAGATCAGGTATACCTTCATGATGAGCGGA 3696

QY 643 catatcagcaagatgagatgagcttgaatgcttctgagatgagatgagatgagat 702
 DB 3695 CATTCACATTAACGACAAAGTACATGTTACTCTTAAATGCTTCTGACATGCG 3696

QY 703 caaagcaatitaaatgactgactatagatatagaagagactctctatcttctatct 762
 DB 3695 CAGAGAGACCGGTTGATTCAGAGCAGAGATCAGGTATACCTTCATGATGAGCGGA 3696

QY 763 gacaaagcaatgactgactatagatgagatgagatgagatgagatgagatgagatgag 822

DB 3575 GTATCTATCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT 3576

QY 823 ccaactgttacttgatgagacatgagcaaaacagcaagctgagaaatlltaacaaagaa 882

DB 3515 CCACTTCATCTTGGCACTTAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 3456

QY 883 aaagcaatitaaatgactgactatagatatagaagagactctctatcttctatct 942

DB 3455 CCACTTCATCTTGGCACTTAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 3456

QY 943 tctgagacagatgagatgagatgagatgagatgagatgagatgagatgagatgagat 1002

DB 3395 GAGGATCTCTTGAAG 3396

QY 1003 gatctatctgacacagcagcaqatatact 1045

DB 3335 AGGAAGCAGGATATACCGCTTACATCTGCT 3303

Search completed: March 9, 2002, 02:21:27
 Job time: 6251 sec